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Abstract: Objectives: To compare the survival rate, and the clinical and laboratory characteristics in patients, character-
ized by the presence of certain anti-neutrophil cytoplasmic auto-antibodies (ANCAs). 
Methods: In a retrospective observational study, we analyzed the data of all patients with a positive ANCA test between 
1995 and 2005 at our hospital. Based on serology patients were divided in three subgroups (ANCA-Proteinase 3 (PR3), 
ANCA-Myeloperoxidase (MPO) and atypical ANCA), irrespective of the diagnosis. Patient survival was compared by 
Kaplan Meier survival analysis. Differences in clinical and laboratory characteristics between the groups of specific AN-
CAs were determined. 
Results: Fifty-four ANCA-positive patients were analyzed. Eighteen of these patients were ANCA-PR3-positive, 17 were 
ANCA-MPO-positive and 19 had a atypical ANCA. A random control group was created of matched ANCA negative pa-
tients. Average follow-up time was 52 months. The calculated five year survival rate in respectively the ANCA-PR3-
positive group, the ANCA-MPO-positive group, the atypical ANCA group and the ANCA-negative group was 45%, 81%, 
90% and 100%. (P = 0.012, Wilcoxon test). A higher mean leukocyte count, a higher mean erythrocyte sedimentation rate 
and more fever was observed in the ANCA-PR3-positive group compared to the ANCA-MPO-positive group. 
Conclusions: A remarkable lower survival rate was observed in ANCA-PR3-positive patients compared to ANCA-MPO-
positive patients. We also demonstrated that patients characterized by the presence of a defined ANCA differ in clinical 
and laboratory characteristics. 
Keywords: ANCA, anti-myeloperoxidase (MPO), anti-proteinase3 (PR3), survival, prognostic value. 
INTRODUCTION 
  Anti-neutrophil cytoplasmic auto-antibodies (ANCAs) 
are important serologic markers for vasculitis. ANCA-
associated diseases comprise a heterogeneous group of dis-
eases that are generally considered uncommon, containing 
not only vasculitides, but also a variety of other (systemic) 
diseases [1, 2]. 
  ANCAs are directed against several myeloid enzymes. 
By indirect immunofluorescence microscopy on neutrophils 
two major categories can be distinguished: cytoplasmic 
ANCA and perinuclear ANCA. By ELISA testing cytoplas-
mic ANCA nearly always reacts with proteinase 3 (ANCA-
PR3). The major perinuclear ANCA target is myeloperoxi-
dase (ANCA-MPO). In atypical ANCAs the immunofluores-
cence test is positive (mostly perinuclear ANCA), but the 
ELISA for both ANCA-MPO and ANCA-PR3 is negative. 
  Data from recent studies seem to confirm the long- dis-
puted pathogenic role of ANCAs [3, 4]. ANCA-PR3-posi-
tivity is predominantly found in patients with Wegener’s   
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granulomatosis and microscopic polyangiitis. ANCA-MPO-
positivity is also found in patients with microscopic poly-
angiitis as well as in patients with other vasculitides and 
auto-immune conditions [1]. Atypical ANCAs are seen in a 
wide variety of medical conditions. 
  Most prospective studies compare characteristics of 
ANCA subgroups within a certain diagnosis and with strict 
entry criteria. Few studies used the ANCA serology as entry 
point for analysis. Former studies showed that in patient with 
Wegener’s granulomatosis ANCA-PR3-positive patients 
have more relapses and a shorter survival period compared to 
ANCA-MPO-positive patients [5,6]. In a cohort of patients 
with Wegener’s granulomatosis or microscopic polyangiitis, 
a poorer prognosis was found in patients with ANCA-PR3 
positivity compared to patients with ANCA-MPO positivity 
[7, 8]. 
  The objective of this study was to compare the survival 
rate, and the clinical and laboratory characteristics in pa-
tients, characterized by the presence of ANCA-MPO and 
ANCA-PR3, irrespective of the diagnosis. All new ANCA-
positive patients over a 10-year period at our hospital, were 
analyzed. In contrast to former studies, the different sero-
logic subgroups were compared irrespective of the diagnosis 
and without strict entry criteria. ANCA testing was per-
formed in cases with clinical suspicion of a systemic disease.  
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Firstly the survival rates of the different serologic subgroups 
were investigated. Secondly differences in clinical and labo-
ratory characteristics were determined. We tried to formulate 
which combination of clinical parameters correlated with the 
presence of a positive ANCA. 
MATERIAL AND METHODOLOGY 
  A retrospective study was performed at Ikazia Hospital, a 
general teaching hospital in Rotterdam, the Netherlands. All 
patients, who had been tested for the first time for ANCA 
serology between 1995 and 2005, were identified by Sanquin 
(central laboratory, Amsterdam). Detection of ANCA by 
immunofluorescence [9] and testing of ANCA target anti-
gens by ELISA [10] were performed according to standard-
ized European guidelines. There were no exclusion criteria. 
  Fifty-four ANCA-positive patients were analyzed. Eight-
een patients were ANCA-PR3 positive, 17 were ANCA-
MPO positive and 19 had an atypical ANCA. A random con-
trol group was created of ANCA negative patients, matched 
for age and gender. Starting date of study entry was the date 
of the first ANCA serology. 
  Clinical, laboratory and survival data were collected ret-
rospectively from the patients’ charts. Treatment was not 
uniform because of the wide variety of diagnoses. Part of the 
patients received immunosuppressive drugs. Analyses were 
performed with all ANCA positive patients and a matched 
sample of ANCA negative patients. 
  Baseline characteristics of the different groups were 
compared. We constructed Kaplan-Meier survival curves for 
the different ANCA subgroups. Starting date for the curves 
was the date on which ANCA serology was obtained. The 
generalized Wilcoxon (Breslow) test was performed to test 
the equality of survival distributions for the different sub-
groups. 
  The relevant clinical and laboratory differences between 
the groups were analyzed. 
  Differences between means were tested using the Stu-
dent’s t-test. The chi-square test was used to compare cate-
gorical data. All tests were two-tailed and P-values of < 0.05 
were considered significant. Analyses were performed with 
SPSS version 14.0 (SPSS Inc., Chicago, IL, USA). 
RESULTS 
  Fifty-four patients had a positive ANCA immunofluores-
cence test. These patients were divided into three subgroups. 
A random control group of ANCA-negative patients was 
created. The indication to test for ANCA was in all cases a 
clinical suspicion of the presence of an auto-immune disease. 
  Mean follow-up time was 52 months. Mean follow-up 
time in the atypical ANCA group was 72 months (signifi-
cantly higher). Mean age was 56 years. There were no sig-
nificant differences in mean age and sex distribution between 
the groups. Fifty-seven percent of the patients underwent 
tissue biopsy. The diagnoses were classified according tot 
the international classification of diseases (ICD-10). Diagno-
sis in the ANCA-PR3-positive group was mostly Wegener’s 
granulomatosis (72%). Other diagnoses in the ANCA-PR3-
positive group were: Churg-Strauss, sarcoidosis, idiopathic 
pulmonary fibrosis, polyarteritis nodosa and hypersensitivity 
angiitis. In the ANCA-MPO-positive group one patient was 
 
Fig. (1). Calculated five year survival in respectively the ANCA-PR3-positive group, the ANCA-MPO-positive group, the atypical ANCA 
group and the ANCA-negative group. The curves differ significantly (P=0.012, Wilcoxon test). 
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diagnosed with Wegener’s granulomatosis. Other diagnoses 
in the ANCA-MPO-positive group were: systemic lupus 
erythematosus, seronegative rheumatoid arthritis, idiopathic 
pulmonary fibrosis, microscopic polyangiitis, giant cell ar-
teritis, polymyalgia rheumatica and Sjögren’s syndrome. 
Diagnoses in the atypical ANCA group were among others: 
mixed connective tissue disease, polymyositis, systemic scle-
rosis and Crohn’s disease. 
  The calculated five year survival rate in respectively the 
ANCA-PR3-positive group, the ANCA-MPO-positive group, 
the atypical ANCA group and the ANCA-negative group 
was 45%, 81%, 90% and 100% (Fig. 1). The generalized 
Wilcoxon (Breslow) test was performed to test the equality 
of survival distributions for the different subgroups. The 
survival curves differed significantly (P = 0.012). 
 Table  1 shows the differences in laboratory and clinical 
characteristics, comparing the ANCA-PR3-positive group 
with the ANCA-MPO-positive group. The laboratory results 
showed significant differences in mean leukocyte count and 
erythrocyte sedimentation rate (ESR) between the sub-
groups. The incidence of erytrhocyturia and proteinuria was 
higher in the ANCA-PR3-positive group. No significant dif-
ferences were seen in hemoglobin level and platelet count. 
Ear-nose-throat symptoms and fever were observed more 
often in the ANCA-PR3-positive group. No significant dif-
ferences were seen in the incidence of dyspnoe and weight 
loss. 
Table 1.  Differences in Laboratory and Clinical Characteris-
tics, Comparing the ANCA-PR3-Positive Group 
with the ANCA-MPO-Positive Group 
 
  ANCA-PR3+ ANCA-MPO+ P-Value 
Leukocyte count (*109/l)  13.4 8.7  0.001 
Hemoglobin (mmol/l)  6.9  7.6  0.144 
Platelet count (*109/l)  371  305  0.090 
Mean ESR (mm/hr)  86  58  0.010 
Erytrocyturia (%)  81  38  0.012 
Proteinuria (%)  88  50  0.022 
Dyspnoe (%)  39  41  0.890 
Fever (%)  56  12  0.006 
Weight loss (%)  56  41  0.395 
Mean values or percentages given with p-values. 
 
  The conclusion can be drawn that the triad elevated ESR, 
erythrocyturia and malaise might be useful when considering 
ANCA testing. The combination of these three characteris-
tics was seen in 73 percent of the patients in the ANCA-
PR3-positive group. In the ANCA-negative group no pa-
tients had the combination of these characteristics. 
DISCUSSION 
  A remarkable difference in survival rate was observed in 
patients characterized by the presence of a defined ANCA. 
ANCA-PR3-positive patients showed a poor prognosis com-
pared to ANCA-MPO-positive patients. 
  We could demonstrate that patients characterized by the 
presence of a defined ANCA differ not only in diagnoses, 
but also in a variety of clinical and laboratory characteristics. 
ANCA-PR3-positive patients demonstrated a more extensive 
disease state. The triad elevated ESR, erythrocyturia and 
malaise was observed more often in ANCA positive patients 
and can therefore be used as a clinical prediction estimate, 
when considering obtaining ANCA serology. 
  Previous studies have shown a lower survival rate in 
ANCA-PR3 patients [5, 7], compared to ANCA-MPO pa-
tients. Most of these studies analyzed the value of specific 
ANCAs within specific diagnostic subgroups, while we in-
cluded all ANCA positive patients irrespective of the diag-
nosis. As far as we know there is only one other study, which 
used the serology as entry point for analysis [11]. In that 
study no difference in survival between ANCA-PR3 and 
ANCA-MPO was found. The survival rate, we found in 
ANCA-PR3 positive patients is lower then reported on large 
cohorts of PR3-ANCA positive patients with vasculitis [1, 
13]. We included all PR3 positive patients irrespective of the 
diagnoses, while earlier studies had strict entry criteria and 
included only patients with a biopsy-proven diagnosis. So 
the survival rate in earlier studies might be overestimated 
because patients with a worse prognosis (e.g. elderly) were 
excluded. 
  We found clear differences in laboratory and clinical 
parameters between the different groups. ANCA-PR3 pa-
tients demonstrated a more aggressive disease state. They 
have more extensive inflammation parameters. This con-
firms the findings of previous studies [2, 6, 12]. 
  The three subgroups (ANCA-PR3, ANCA-MPO and 
atypical ANCA) were equally distributed in our population. 
ANCA testing is often done with a low pre-test probability 
of systemic small vessel vascultis. A more critical approach 
in obtaining ANCA tests will increase the diagnostic value 
of ANCA-testing [8, 14]. The investigated clinical and labo-
ratory characteristics and the proposed triad could help when 
ANCA testing is considered. In our opinion ANCA testing 
should only be performed when there is a fair clinical suspi-
cion of an ANCA-associated vasculitis. 
  The numbers in both groups are small. Because of lack of 
power, we could not exclude that the differences in survival 
rate between ANCA-PR3 and ANCA-MPO-positive patients 
are partly based on differences in diagnoses in the groups. 
The small numbers in the subgroups underscore the fact that 
ANCA-related diseases are seldom seen in general hospitals. 
For example, when taking into account the incidence of 
Wegener’s granulomatosis and the adherence population of 
Ikazia Hospital, we expected one or two new patients per 
year. The low incidence of these diseases is an argument to 
enroll all new patients in prospective studies. 
  In clinical practice ANCA serology is mainly used as a 
diagnostic tool, in combination with tissue examination. 
Next to the diagnostic significance of the ANCA serology, 
this retrospective study demonstrates the prognostic value of 
the specific ANCA-positivity. 
  Because of the low incidence of ANCA-associated dis-
eases, to define the clinical and prognostic value of (specific) 
ANCA-serology more extensive (probably multi-center) and 
prospective research is necessary. ANCA Subtype: Survival and Clinical Presentation  The Open Rheumatology Journal, 2009, Volume 3    17 
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